Abstract

28
29
IMRT planning with commercial TPSs is a trial-and-error process. Consequently, the quality of 30 treatment plans may not be consistent among patients, planners and institutions. Recently, 31 different plan quality assurance (QA) models have been proposed, that could flag and guide 32 improvement of suboptimal treatment plans. However, the performance of these models was 33 validated using plans that were created using the conventional trail-and-error treatment 34 planning process. Consequently, it is challenging to assess and compare quantitatively the 35 accuracy of different treatment planning QA models. Therefore, we created a golden standard 36 dataset of consistently planned Pareto-optimal IMRT plans for 115 prostate patients. Next, the 37 dataset was used to assess the performance of a treatment planning QA model that uses the 38 overlap volume histogram (OVH). 39 40
Introduction
18
Intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) have 19 increased the organ sparing potential for prostate patients compared to 3D conformal 20 radiotherapy (3D-CRT) (Palma et al., 2008) . Because IMRT/VMAT planning with the current 21 commercial treatment planning systems (TPSs) is a trial-and-error process, based on a series of 22 subjective human decisions, the quality of the IMRT/VMAT treatment plans may not be 23 consistent among patients, planners or institutions with different experience (Nelms et al., 24 2012 ). 25 26 To ensure consistent high quality treatment plans, several groups have developed treatment 27 plan quality assurance (QA) models, which predict the feasible dose levels for the organs at risk 28 (OARs). The achieved dose of a treatment plan can be compared with the predicted dose by 29 such a plan QA model to determine if the OARs can be spared further. In most studies, the prediction accuracy of the plan QA models was assessed by comparing the 7 predictions with the achieved plans generated with the same trial-and-error planning process 8 as used in clinical practice. Therefore, the plans that are used to validate the models may be 9 suboptimal (not Pareto-optimal) and with inconsistent tradeoffs among sparing different OARs 10 while ensuring sufficient PTV coverage. Consequently, it is unclear if an observed prediction 11 error is due to the inherent limitation of the model, or due to the non-optimality of the 12 treatment plans used for validation, or due to different tradeoffs of sparing multiple OARs. As a 13 result, accurate establishment of the inherent prediction accuracy of most plan QA models is 14
lacking. This hampers the comparison of the performance of different treatment planning QA 15 models and may hamper the clinical introduction of any of such models. 16 17 In recent years we have developed Erasmus-iCycle, an algorithm for fully automated generation 18 of Pareto-optimal treatment plans with consistent priorities (Breedveld et al., 2012) . With 19 Erasmus-iCycle, a protocol specific wish list is used. The wish list reflects the goals of our 20 radiation oncologists with respect to PTV coverage and OAR sparing for a certain protocol and 21 employs hard constraints and objectives in a predefined order of priority. Each treatment plan 22 that was generated using the same wish list, is Pareto optimal and reflects the same balance 23 between the different treatment planning tradeoffs. Therefore Erasmus-iCycle is able to 24 generate a dataset that can be considered as the ground truth to evaluate the performance of 25 different treatment planning QA models. 26 27 The purpose of the current study was threefold: (i) to create a dataset of Pareto optimal 28 treatment plans for prostate cancer patients that can be considered as the ground truth for the 29 evaluation of the performance of treatment planning QA models; ii) to make this dataset 30 publicly available to the radiotherapy community so that any groups can train and evaluate the 31 performance of their models on a common dataset; (iii) to validate the performance of one of 32 the published models, namely the OVH model, for prostate cancer patients treated with 33 IMRT/VMAT. 34 35
Materials and Methods
36
Patients and treatment plans
37
This study includes all prostate cancer patients treated in 2014 at our institute that had an 38 estimated 10%-25% risk of tumor cells in the seminal vesicles. For 115 patients all relevant data 39 could be retrieved and these patients were included in the analyses. The prostate was 40 considered as the high risk CTV. The PTV1 was equal to the CTV expanded with a margin of 5 41 mm (7 mm in caudal direction). The PTV2 composed PTV1 including the seminal vesicles that 1 were expanded by an isotropic margin of 8 mm (Mutanga et al., 2011) .The prescribed dose was 2 78 Gy to PTV1 and 72.2 Gy to PTV2 in 39 fractions. For all patients VMAT treatment plans were 3 generated using a simultaneously integrated boost technique. 4 5
At our institute all VMAT plans are fully automatically generated in a 2-step process (Voet et al., 6 2014). In the first step, Erasmus-iCycle was used for automated generation of a 23-equiangular 7 -beam IMRT treatment plan, using hard constraints and prioritized objectives for consistent 8 steering of the multi-criterial plan optimization (see next section). In the next step, the resulting 9 DVH parameters for target and OARs were used to generate for each patient an individualized 10 Monaco template, that was used to produce the final treatment plan using our clinical TPS 11 (Monaco, version 3.3 -5.0, Elekta AB, Sweden). Generation of the Erasmus-iCycle plan, the 12
Monaco template and the final Monaco plan were fully automated. This procedure allows plans 13 generated by an in-house developed software to be delivered clinically. Previously we 14 demonstrated that the automated process resulted in equal or better plan quality compared to 15 conventional manual planning with the clinical TPS by an expert planner in absence of 16 limitations in planning time (Voet et al., 2014) . And deviations between the Erasmus-iCycle plan 17 and the final plan generated with the clinical TPS are generally small (Voet et al., 2014) . 18
However, to get a maximally consistent dataset, this study was performed using the original 19
Erasmus-iCycle plans. 20 21
Multi-criterial plan generation with Erasmus-iCycle
22
The treatment planning goals were: 99% of both PTVs needed to receive at least 95% of the 23 prescribed dose (78 Gy for PTV1 and 72.2. Gy for PTV2); the rectum volumes that received 24 more than 65 Gy (V 65 ) and 75 Gy (V 75 ) needed to be lower than 30% and 10%, respectively; the 25 mean dose to the anus had to be lower than 45 Gy; and the maximum dose to the femoral 26 heads could not exceed 55 Gy. 27 28 Table 1 shows how these goals and their order of priority were translated into a wish list using 29 hard constraints and objectives with assigned priorities. This wish list was generated in close 30 collaboration between physicists and radiation oncologists and is used as well in clinical 31 practise. All the cost functions that are used are convex and therefore the global optimum is 32 guaranteed to be found (Breedveld et al., 2009 Voet et al., 2014) . Apart from the common mean and maximum dose 37 cost functions, Erasmus-iCycle also uses the Logarithmic Tumor Control Probability (LTCP) 38 (Alber and Reemtsen, 2007) and the generalized equivalent uniform dose (gEUD) (Niemierko, 39 1999) cost functions. The LTCP cost function is defined as: 40
Where N is the number of voxels in the volume, D i is the dose to the i th voxel, D p is the 1 prescribed dose and α is a predefined cell sensitivity parameter. The LTCP cost function controls 2 PTV coverage. If the dose in each PTV voxel is equal to the prescribed dose, the LTCP equals to 1. 3 Voxels with a dose lower than the prescribed dose add to the penalty exponentially. If the dose 4 is higher than the prescribed dose, then the LTCP value will slowly drop to 0. In our experience, 5 the cell sensitivity parameter α = 0.8 results in acceptable coverage for the PTV for the far 6 majority of patients. 7 8 For the rectum, two gEUD cost functions were applied, described by 9
where a is a user-defined parameter, D i is the dose to the i th voxel in the OAR, and N is the 11 number of total voxels in the OAR. The applied a = 12 and a = 8 were used to minimize delivery 12 of high and intermediate-to-high doses to the rectum. 13 14
For the bladder and anus, only the mean dose was minimized. To yield conformal dose 15 distributions without hotspots in unspecified tissue, shells around the PTV and a shrinkage of 16 the patient contour were created and applied. 17 18 
Where v is the volume of interest; D v is the dose to the OAR at volume v; i is the index of a prior 4 patient and N is the total number of prior patients. 5
The assumption that the dose decreases with distance from the PTV is valid when the mean 6 dose to an OAR (or the dose to a large subvolume of an OAR) is planned (optimized) to be as 7 low as possible, as is the case for the rectum, bladder and anus, but e.g. not for the spinal cord 8 (Petit and van Elmpt, 2015) . Since points further away from the PTV can be spared more easily 9 than points closer to the PTV, lowering the mean dose to the OAR will in general lead to a 10 strong decreasing dose-distance relation. 11
However to ensure sufficient PTV coverage, for points of an OAR that are inside the PTV (i.e. r < 12 0), the primary goal is to ensure sufficient dose, instead of as little as possible. From this point 13 of view, it is more difficult to deliver high dose to a point (within the PTV) closer to the PTV 14 boundary than to a point more centrally located in the PTV. So for a certain v that r v < 0 (i.e., 15 within the PTV), more difficult patients have larger (i.e. less negative) r. Therefore for points 16 within the PTV, the predicted dose is given by: 17
For simultaneous integrated boosts (SIB) plans, the doses to points of the OAR are related to 20 the distances to the surfaces of both the low dose PTV (PTV1) and the boost PTV (PTV2), 21 especially for the subvolumes that are inside PTV2 but outside PTV1. For a point in such 22 subvolume, it becomes more difficult to deliver sufficient dose as the distance to the PTV2 23 boundary decreases and the distance from the PTV1 boundary increases (See Figure 1) . For the 24 subvolumes that are outside the PTV, we only consider the doses to PTV2 surface. This more detailed specification of the OVH was not described previously, because in prior 14 studies the volumes of interests were not completely located within the PTV (Wu et al., 2009; 15 Wu et al., 2011), i.e., r v >0. In the current study we attempt to predict the entire DVH. Because 16 the rectum and bladder (can) partly overlap with the PTV, this specification was necessary to 17 predict the dose to the high dose volumes of the DVH. 18 Entire DVHs were predicted by repeating the procedure described above for relative volumes 19 ranging from 0 to 100% in steps of 0.5%. For the data points that could not be predicted (no 20 candidates for prediction found in training cohort), the predicted doses were linearly 21 interpolated by the surrounding predictable DVH points. Because the predicted DVH points of 22 the current patient may be derived from data points of different prior patients, the predicted 23
DVHs might be noisy and not always monotonically decreasing. Therefore, finally the predicted 24
DVHs were smoothed three times by average filters with window widths of 8%, 5% and 2% of 25 the relative volumes, respectively. With the larger windows large peaks could be reduced while 26 the smaller windows reduced smaller peaks. The windows widths were selected based on 27 empirical observations. A typical example is shown in Figure S1 of the supplementary materials. 28
Model evaluation
1
The 115 patients were randomly divided into a training group (N=58) and a validation group 2 (N=57). For each patient in the validation group, the DVHs of the rectum, anus, and bladder 3 were predicted by the QA model, based on the patients in the training group. The performance 4 of the prediction model was assessed by comparing predictions of rectum D mean , V 65 , and V 75 , 5 and the D mean of the anus and bladder with the corresponding values in the Erasmus-iCycle 6 plans. 7 8 To investigate whether the size of the training dataset affects the performance of the model, 9
the DVHs of each patient in the validation group were also predicted by a leave-one-out 10 method, i.e., for each of these 57 patients, the training group consisted of all other 114 patients. 11 12
Influence of inconsistent treatment planning priorities
13
The balance between different treatment plan tradeoffs affects the final plan. If this balance 14 varies among patients in the training set, the model may be over optimistic. For instance, 15
consider the example where for one patient in the training cohort the rectum is sacrificed to 16 optimally spare the bladder, and for another vice versa. The OVH model may select the first 17 patient to predict the bladder dose and the second to predict the rectum dose, while in reality 18 it is impossible to optimally spare both simultaneously. This effect is likely to occur when the 19 prioritization of the different planning goals is not consistent among patients, which is often the 20 case in clinical practice. 21 22
To investigate this effect, another set of Erasmus-iCycle plans were generated. In this dataset, 23 half of the plans in both training and validation cohort were generated with the clinical wish list 24 (Table 1) , and the other half was generated with enhanced bladder sparing at the expense of 25 rectum sparing, achieved by increasing the priority of the bladder mean dose objective to 3, 26 and lowering the priority of all remaining cost functions by one. As a result, both training and 27 validation cohort consisted of plans yielded from two different wish lists. Next the new training 28 plans were used to train the OVH model, and the predicted rectum Dmean, V65 and V75 were 29 validated on the new validation plans. 30 31 32
Statistics
33
Pearson's correlation coefficients (r) were calculated to investigate the correlation between the 34 predicted and achieved DVH metrics. Results are expressed as mean ± 1 standard deviation 35 (SD). All analyses with performed with Erasmus-RTStudio in combination with python 2.7. 36
Results
38
The median volumes of PTV1 and PTV2 were 115.6 cc (range: 62.4 cc -263.3 cc) and 173.4 cc 39 (range: 105.0 cc -295.5 cc), respectively 40
Erasmus-iCycle plans
1
A dataset of Pareto optimal treatment plans with consistent treatment planning priorities was 2 created and made publicly available (Petit, 2015 Increasing the training data set from 58 to 114 patients did not lead to a considerable reduction 3 in prediction errors, expect in V 65 for patients with large achieved V 65 values (above 20%), as is 4 shown in Figure 5 . The prediction accuracy for the other DVH parameters are presented in 5 Table S1 in the supplementary materials. 6 7 Figure 6 shows the prediction accuracy for the rectum when the priority of the bladder is 14 increased compared to the rectum for half of the plans in the training and validation dataset. 15
The difference between prediction and validation increased by 2 Gy (on average), to -2.2±3. 1 16 Gy for Dmean, -2.1±2.6 % for V65 and 0.4±1.5 % for V75. This suggests that the expected, 17 apparent accuracy of the OVH model decreases when the treatment plans in the training and 1 validation database have not been generated with consistent planning priorities. 
Discussion
The quality and consistency of IMRT/VMAT plans may vary among patients and dosimetrists. 10 Plan QA models can help to ensure a high consistency and high quality for treatment plans. were generated by the same trial-and-error treatment planning process that may lead to 15 suboptimal plans, as for which treatment plan QA is intended in the first place. Therefore, in 16 the current study, treatment plans for 115 prostate cancer patients were fully automatically 17 generated with lexicographic multi-criteria optimization, resulting in Pareto optimal treatment 18 plans with a consistent balance between the various treatment planning tradeoffs. This dataset 19
can be used as golden standard to validate, compare and develop new treatment plan QA 20 methods and is made publicly available (Petit, 2015 Figure S2 ). The bladder D mean on the other hand was systematically 4 underestimated by the OVH model by 4.8 Gy with a larger standard deviation. A systematic 5 error can be corrected simply by increasing/decreasing all predictions by the size of that error. 6
The size of the SD has more impact on the clinical suitability of a model, because it determines 7 the width of the confidence interval to distinct sub-optimal plans from prediction errors. E.g. 8 with a confidence of 95%, only differences larger than a threshold of 1.96 times the SD can be 9 attributed to sub-optimality of the plans, given that systematic errors are predicted for. These 10 thresholds were 1.7 Gy (rectum), 3.1 (anus) and 8.0 Gy (bladder) in the current study which 11 makes the model very suitable for the rectum and anus but less for the bladder. 12 13
The large prediction errors of the bladder compared to the rectum and anus can partly be 14 explained by their priorities (high for rectum, low for bladder) in the planning process. When the training and validation groups consist of a mix of plans generated with two different 26 wish lists (high-prioritized and low-prioritized bladder sparing), the apparent accuracy of the 27 OVH model substantially decreased. This finding indicates the dependence of the accuracy of 28 the model on the consistency of the training dataset. In addition, it shows that by using 29 inconsistent planning priorities among the plans in the validation set, the apparent accuracy of 30 the model is lower than the real accuracy, which confirms the need for Pareto optimal, highly 31 consistent validation data to assess the performance of planning QA models. Our previous 32 study (Wang et al., 2013) . also showed that if the training dataset were not consistent, the 33 performance of the planning QA model could be misinterpreted. PTVs. However, the predicted doses were mostly lower than the lowest prescribed doses, 2 which means outside the PTVs. In this study we have shown that it is also possible to accurately 3 predict doses within the overlap region of an OAR and the PTVs for SIB patients. 4 5
In principle, Erasmus -iCycle, as an automated plan generation tool, could also be applied as a 6 planning QA tool for commercial planning systems. It overcomes the limitations of some of the 7 'simplistic' assumptions of the OVH model and therefore provides more sophisticated estimates 8 on the achievable dose to the OARs. . However, Erasmus-iCycle can be considered a full TPS, 9 requiring similar costs in setup and maintenance, and computing power as a commercial TPSs. 10 An investment in Erasmus-iCycle just for treatment planning QA may be too large . Therefore 11
here we made Erasmus-iCycle plans available to improve and validated more 'light weight ' 12 treatment planning QA models. 13 14
In the era of automated treatment planning one could expect that the need for treatment 15 planning QA reduces. However, we see a clear role for QA for automated treatment planning. If 16 something in the fully automated treatment planning chain goes awry (mismatched structures, 17 software bugs etc), this could potentially result in a plan that is of significantly lower quality 18 than necessary, but not low enough for the physician to detect during the plan approval phase. 19 Especially if the quality of automatically generated plans is of consistent high and unrivaled 20 quality (i.e. cannot be improved by an experienced planner), criticism could start to impair. The 21 OVH method is totally independent of the Erasmus-iCycle and therefore we are currently 22 evaluating it as a sanity check for routine QA of automatically generated treatment plans. 23
Conclusions
25
For 115 prostate cancer patients, a Pareto-optimal treatment plan was generated with 26 lexicographic multi-criterial optimization. This plan data set is highly suited for assessing the 27 performance of models for treatment plan QA and has been publicly available for development 28 and validation of treatment planning QA model. We tested the overlap volume histogram 29 (OVH) based QA model, using the generated dataset. It was shown that the OVH model had a 30 very high prediction accuracy for rectum and anus, while for bladder the accuracy was lower. 31 32
